<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34397557</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectal Cancer in Adolescent and Young Adult Patients: Pattern of Clinical Presentation and Case-Matched Comparison of Outcomes.</ArticleTitle><Pagination><StartPage>1064</StartPage><EndPage>1073</EndPage><MedlinePgn>1064-1073</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002022</ELocationID><Abstract><AbstractText Label="BACKGROUND">Rectal cancer in adolescents and young adults (age &#x2264;39) is increasing. Early diagnosis is a challenge in this subset of patients.</AbstractText><AbstractText Label="OBJECTIVE">This study aims to analyze the presentation pattern and outcomes of sporadic rectal cancer in adolescents and young adults.</AbstractText><AbstractText Label="DESIGN">This is a retrospective study.</AbstractText><AbstractText Label="SETTING">This study was conducted at 3 European tertiary centers.</AbstractText><AbstractText Label="PATIENTS">Data on adolescents and young adults operated on for sporadic rectal cancer (January 2008 through October 2019) were analyzed. To compare outcomes, adolescents and young adults were matched to a group of patients aged &#x2265;40 operated on during the same period.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcomes measured were clinical presentation and long-term outcomes.</AbstractText><AbstractText Label="RESULTS">Sporadic rectal cancers occurred in 101 adolescents and young adults (2.4%; mean age, 33.5; range, 18-39); 51.5% were male, and a smoking habit was reported by 17.8% of patients. The rate of a family history for colorectal cancer was 25.7%, and of these patients, 24.7% were obese. Diagnosis based on symptoms was reported in 92.1% patients, and the mean time from first symptoms to diagnosis was 13.7 months. The most common symptom at diagnosis was rectal bleeding (68.8%), and 12% and 34% of the adolescents and young adults presented with locally advanced or metastatic disease at diagnosis. Consequently, 68.3% and 62.4% adolescents and young adults received neoadjuvant and adjuvant treatments. The rate of complete pathological response was 24.1%; whereas 38.6% patients had stage IV disease, and 93.1% were microsatellite stable. At a mean follow-up of 5 years, no difference in cancer-specific survival, but a lower disease-free survival was reported in adolescents and young adults (p &lt; 0.0001) vs the matched group. Adolescents and young adults with stages I to II disease had shorter cancer-specific survival and disease-free survival (p = 0.006; p &lt; 0.0001); with stage III disease, they had a shorter disease-free survival (p = 0.01).</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by its observational, retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS">The significantly delayed diagnosis in adolescents and young adults may have contributed to the advanced disease at presentation and lower disease-free survival, even at earlier stages, suggesting a higher metastatic potential than in older patients. See Video Abstract at http://links.lww.com/DCR/B537.</AbstractText><AbstractText Label="CNCER DE RECTO EN PACIENTES ADOLESCENTES Y ADULTOS JVENES CUADRO DE PRESENTACIN CLNICA Y COMPARACIN DE DESENLACES POR CASOS EMPAREJADOS">ANTECEDENTES:El c&#xe1;ncer de recto en adolescentes y adultos j&#xf3;venes (edad &#x2264; 39) est&#xe1; aumentando. El diagn&#xf3;stico temprano es un desaf&#xed;o en este subgrupo de pacientes.OBJETIVO:Analizar el cuadro de presentaci&#xf3;n y los desenlaces en adolescentes y adultos j&#xf3;venes con c&#xe1;ncer de recto espor&#xe1;dico.DISE&#xd1;O:Estudio retrospectivo.&#xc1;MBITO:Tres centros europeos de tercer nivel.PACIENTES:Se analizaron los datos de adolescentes y adultos j&#xf3;venes operados de c&#xe1;ncer de recto espor&#xe1;dico (enero de 2008 - octubre de 2019). Para comparar los desenlaces se emparej&#xf3; a adolescentes y adultos j&#xf3;venes con un grupo de pacientes mayores de 40 a&#xf1;os operados en el mismo per&#xed;odo de tiempo.PRINCIPALES VARIABLES ANALIZADAS:Cuadro cl&#xed;nico, resultados a largo plazo.RESULTADOS:Los c&#xe1;nceres de recto espor&#xe1;dicos en adolescentes y adultos j&#xf3;venes fueron 101 (2,4%, edad media: 33,5, rango 18-39). El 51,5% eran hombres, el 17,8% de los pacientes fumaba. El 25,7% tent&#xed;a antecedentes familiares de c&#xe1;ncer colorrectal. El 24,7% eran obesos. El diagn&#xf3;stico con base en los s&#xed;ntomas se inform&#xf3; en el 92,1% de los pacientes, el tiempo promedio desde los primeros s&#xed;ntomas hasta el diagn&#xf3;stico fue de 13,7 meses. El s&#xed;ntoma m&#xe1;s com&#xfa;n en el momento del diagn&#xf3;stico fue el sangrado rectal (68,8%). 12% y 34% de adolescentes y adultos j&#xf3;venes presentaron enfermedad localmente avanzada o metast&#xe1;sica en el momento del diagn&#xf3;stico. Por lo tanto, el 68,3% y el 62,4% de adolescentes y adultos j&#xf3;venes recibieron neoadyuvancia y adyuvancia. La tasa de respuesta patol&#xf3;gica completa fue del 24,1%; mientras que el 38,6% estaban en estadio IV. El 93,1% eran microsatelite estable. Con una media de seguimiento de 5 a&#xf1;os, no se observaron diferencias en la sobrevida espec&#xed;fica del c&#xe1;ncer, pero se inform&#xf3; una menor sobrevida libre de enfermedad en adolescentes y adultos j&#xf3;venes (p &lt;0,0001) frente al grupo emparejado. Los adolescentes y adultos j&#xf3;venes en estadios I-II tuvieron una sobrevida espec&#xed;fica por c&#xe1;ncer y una sobrevida libre de enfermedad m&#xe1;s corta (p = 0,006; p &lt;0,0001); el estadio III tuvo una sobrevida libre de enfermedad m&#xe1;s baja (p = 0,01).LIMITACIONES:Dise&#xf1;o observacional y retrospectivo.CONCLUSIONES:El diagn&#xf3;stico notablemente demorado en adolescentes y adultos j&#xf3;venes puede contribuir a la presentaci&#xf3;n de una enfermedad avanzada y a una menor sobrevida libre de enfermedad, incluso en estadios m&#xe1;s tempranas, lo cual implica un mayor potencial metast&#xe1;sico en comparaci&#xf3;n con pacientes mayores. Consulte Video Resumen en http://links.lww.com/DCR/B537.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Foppa</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of Colon and Rectal Surgery, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francesca Bertuzzi</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Medical Oncology and Hematology Unit, Humanitas Cancer Center, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cianchi</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Digestive Surgery, Careggi University Hospital, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvello</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of Colon and Rectal Surgery, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maroli</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of Colon and Rectal Surgery, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolthuis</LastName><ForeName>Albert M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Abdominal Surgery, University Hospital Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rimassa</LastName><ForeName>Lorenza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Medical Oncology and Hematology Unit, Humanitas Cancer Center, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laghi</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of Gastroenterology, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montorsi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of General and Digestive Surgery, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Hoore</LastName><ForeName>Andr&#xe9; J L</ForeName><Initials>AJL</Initials><AffiliationInfo><Affiliation>Department of Abdominal Surgery, University Hospital Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of Colon and Rectal Surgery, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008487" MajorTopicYN="N">Medical History Taking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>16</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34397557</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002022</ArticleId><ArticleId IdType="pii">00003453-202109000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Investig Med. 2017;65:311&#x2013;315.</Citation></Reference><Reference><Citation>Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1695&#x2013;1698.</Citation></Reference><Reference><Citation>Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17&#x2013;22.</Citation></Reference><Reference><Citation>Aziz H, Pandit V, DiGiovanni RM, et al. Increased incidence of early onset colorectal cancer in Arizona: a comprehensive 15-year analysis of the Arizona Cancer Registry. J Gastrointest Dig Syst. 2015;5:345&#x2013;348.</Citation></Reference><Reference><Citation>Wu X, Groves FD, McLaughlin CC, Jemal A, Martin J, Chen VW. Cancer incidence patterns among adolescents and young adults in the United States. Cancer Causes Control. 2005;16:309&#x2013;320.</Citation></Reference><Reference><Citation>Teng A, Lee DY, Cai J, Patel SS, Bilchik AJ, Goldfarb MR. Patterns and outcomes of colorectal cancer in adolescents and young adults. J Surg Res. 2016;205:19&#x2013;27.</Citation></Reference><Reference><Citation>O&#x2019;Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866&#x2013;872.</Citation></Reference><Reference><Citation>Haggar FA, Preen DB, Pereira G, Holman CD, Einarsdottir K. Cancer incidence and mortality trends in Australian adolescents and young adults, 1982-2007. BMC Cancer. 2012;12:151.</Citation></Reference><Reference><Citation>Young JP, Win AK, Rosty C, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol. 2015;30:6&#x2013;13.</Citation></Reference><Reference><Citation>Troeung L, Sodhi-Berry N, Martini A, et al. Increasing incidence of colorectal cancer in adolescents and young adults aged 15-39 years in Western Australia 1982-2007: examination of colonoscopy history. Front Public Health. 2017;5:179.</Citation></Reference><Reference><Citation>Yeo H, Betel D, Abelson JS, Zheng XE, Yantiss R, Shah MA. Early-onset colorectal cancer is distinct from traditional colorectal cancer. Clin Colorectal Cancer. 2017;16:293&#x2013;299.e6.</Citation></Reference><Reference><Citation>Davis DM, Marcet JE, Frattini JC, Prather AD, Mateka JJ, Nfonsam VN. Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg. 2011;213:352&#x2013;361.</Citation></Reference><Reference><Citation>Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116(3): 544:573.</Citation></Reference><Reference><Citation>Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109:djw322.</Citation></Reference><Reference><Citation>Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216&#x2013;224.</Citation></Reference><Reference><Citation>You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med. 2012;172:287&#x2013;289.</Citation></Reference><Reference><Citation>Chiang JM, Chen MC, Changchien CR, et al. Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. Dis Colon Rectum. 2003;46:904&#x2013;910.</Citation></Reference><Reference><Citation>Domergue J, Ismail M, Astre C, et al. Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. Cancer. 1988;61:835&#x2013;840.</Citation></Reference><Reference><Citation>O&#x2019;Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28:558&#x2013;562.</Citation></Reference><Reference><Citation>Dozois EJ, Boardman LA, Suwanthanma W, et al. Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome? Medicine (Baltimore). 2008;87:259&#x2013;263.</Citation></Reference><Reference><Citation>Mork ME, You YN, Ying J, et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 2015;33:3544&#x2013;3549.</Citation></Reference><Reference><Citation>Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer. 2016;122:929&#x2013;934.</Citation></Reference><Reference><Citation>Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B; Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8:288&#x2013;298.</Citation></Reference><Reference><Citation>Derwinger K, Kodeda K, Gerjy R. Age aspects of demography, pathology and survival assessment in colorectal cancer. Anticancer Res. 2010;30:5227&#x2013;5231.</Citation></Reference><Reference><Citation>O&#x2019;Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187:343&#x2013;348.</Citation></Reference><Reference><Citation>Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced-stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms or time to diagnosis. Clin Gastroenterol Hepatol. 2017;15:728&#x2013;737.e3.</Citation></Reference><Reference><Citation>Yarden RI, Newcomer KL. Never too young advisory board, Colorectal Cancer Alliance. Young onset colorectal cancer patients are diagnosed with advanced disease after multiple misdiagnoses. AACR Annual Meeting. 2019; abstract 3347/13.</Citation></Reference><Reference><Citation>Bibbins-Domingo K, Grossman DC, Curry SJ, et al.; US Preventive Services Task Force. Screening for colorectal cancer: US preventive services task force recommendation statement [published correction appears in JAMA . 2016;316:545; JAMA . 2017;317(21):2239]. JAMA. 2016;315:2564&#x2013;2575.</Citation></Reference><Reference><Citation>Provenzale D, Gupta S, Ahnen DJ, et al. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. J Natl Compr Canc Netw. 2018;16:939&#x2013;949.</Citation></Reference><Reference><Citation>Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153:307&#x2013;323.</Citation></Reference><Reference><Citation>Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250&#x2013;281.</Citation></Reference><Reference><Citation>Qaseem A, Crandall CJ, Mustafa RA, Hicks LA, Wilt TJ; Clinical Guidelines Committee of the American College of Physicians. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians. Ann Intern Med. 2019;171:643&#x2013;654.</Citation></Reference><Reference><Citation>Chang DT, Pai RK, Rybicki LA, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012;25:1128&#x2013;1139.</Citation></Reference><Reference><Citation>Levine O, Zbuk K. Colorectal cancer in adolescents and young adults: defining a growing threat. Pediatr Blood Cancer. 2019;66:e27941.</Citation></Reference><Reference><Citation>Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003;90:205&#x2013;214.</Citation></Reference><Reference><Citation>Losi L, Di Gregorio C, Pedroni M, et al. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol. 2005;100:2280&#x2013;2287.</Citation></Reference><Reference><Citation>Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193&#x2013;2200.</Citation></Reference><Reference><Citation>Ak S, Tunca B, Yilmazlar T, et al. Microsatellite instability status affects gene expression profiles in early onset colorectal cancer patients. J Surg Res. 2013;185:626&#x2013;637.</Citation></Reference><Reference><Citation>Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13:3831&#x2013;3839.</Citation></Reference><Reference><Citation>Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015;21:5167&#x2013;5175.</Citation></Reference><Reference><Citation>Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012;27:613&#x2013;623.</Citation></Reference><Reference><Citation>Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014;20:6055&#x2013;6072.</Citation></Reference><Reference><Citation>Mehta M, Shike M. Diet and physical activity in the prevention of colorectal cancer. J Natl Compr Canc Netw. 2014;12:1721&#x2013;1726.</Citation></Reference><Reference><Citation>Simons CC, Schouten LJ, Godschalk R, et al. Body size, physical activity, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk. Carcinogenesis. 2015;36:971&#x2013;981.</Citation></Reference><Reference><Citation>Lund EK, Belshaw NJ, Elliott GO, Johnson IT. Recent advances in understanding the role of diet and obesity in the development of colorectal cancer. Proc Nutr Soc. 2011;70:194&#x2013;204.</Citation></Reference><Reference><Citation>Levi Z, Kark JD, Katz LH, et al. Adolescent body mass index and risk of colon and rectal cancer in a cohort of 1.79 million Israeli men and women: a population-based study. Cancer. 2017;123:4022&#x2013;4030.</Citation></Reference><Reference><Citation>Buc E, Kwiatkowski F, Alves A, Panis Y, Mantion G, Slim K. Tobacco smoking: a factor of early onset of colorectal cancer. Dis Colon Rectum. 2006;49:1893&#x2013;1896.</Citation></Reference><Reference><Citation>Gong J, Hutter C, Baron JA, et al. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. Cancer Epidemiol Biomarkers Prev. 2012;21:1974&#x2013;1985.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30047946</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Print"><Volume>154</Volume><Issue>3</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>Factores asociados con supervivencia a cinco a&#xf1;os en ni&#xf1;os con astrocitoma cerebral.</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>286</EndPage><MedlinePgn>283-286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.17003116</ELocationID><Abstract><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">La segunda causa de muerte infantil es el c&#xe1;ncer, del cual las leucemias y los tumores del sistema nervioso central son las presentaciones m&#xe1;s frecuentes; de los &#xfa;ltimos, los astrocitomas representan 40 %.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Identificar los factores asociados con la supervivencia a cinco a&#xf1;os en ni&#xf1;os con astrocitoma cerebral.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">Estudio de casos y controles anidado en una cohorte retrospectiva en pacientes con diagn&#xf3;stico de astrocitoma cerebral que recibieron tratamiento de diciembre de 2006 a enero de 2010. Se realiz&#xf3; estad&#xed;stica descriptiva y prueba de chi cuadrado; para evaluar la supervivencia se utiliz&#xf3; el m&#xe9;todo de Kaplan-Meier.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se incluyeron 21 pacientes con diagn&#xf3;stico de astrocitoma cerebral; la supervivencia fue de 76 % a cinco a&#xf1;os, el astrocitoma piloc&#xed;tico fue el m&#xe1;s frecuente (61 %), con una edad media de siete a&#xf1;os; predomin&#xf3; el sexo masculino, la edad al fallecimiento oscil&#xf3; entre los ocho y 12 a&#xf1;os (p = 0.022); 80 % de los pacientes fallecidos tuvo tumor con localizaci&#xf3;n infratentorial d (RM = 17.3, IC 95 % = 1-622, p = 0.01). No hubo diferencia en la supervivencia atribuible al tratamiento.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">La supervivencia a cinco a&#xf1;os fue de 76 %; el factor de riesgo significativo que la limita es la localizaci&#xf3;n infratentorial del tumor.</AbstractText><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The second cause of children&#x2019;s death is cancer, with leukemia and central nervous system tumors being the most common, among which astrocytomas account for 40%.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To find out the factors associated with 5-year survival in children with cerebral astrocytoma.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Case-control study nested in a retrospective cohort of patients diagnosed with cerebral astrocytoma who received treatment from December 2006 to January 2010. Descriptive statistics and the chi-square test were carried out; the Kaplan-Meier method was used to assess survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-one patients diagnosed with cerebral astrocytoma were included; survival was 76% at 5 years; with pilocytic astrocytoma being the most common (61%); mean age was 7 years, and male gender was predominant; age at death ranged from 8 to 12 years (p = 0.022), with 80% of deceased patients having infratentorial localization (OR = 17.3; 95% CI = 1-622; p = 0.01). There was no treatment-attributable survival difference.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Five-year survival was 76%; the limiting risk factor is tumor infratentorial localization.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2018 Secretar&#xcd;a de Salud.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sevilla-Castillo</LastName><ForeName>Ricardo Arturo</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital de Especialidades 25, Servicio de Pediatr&#xed;a Cl&#xed;nica, Monterrey, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade-Sarmiento</LastName><ForeName>Leticia Aradi</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital de Especialidades 25, Servicio de Pediatr&#xed;a Cl&#xed;nica, Monterrey, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001254" MajorTopicYN="N">Astrocytoma</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Astrocitoma cerebral</Keyword><Keyword MajorTopicYN="N">Cerebral astrocytoma</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer infantil</Keyword><Keyword MajorTopicYN="N">Pediatric cancer</Keyword><Keyword MajorTopicYN="N">Supervivencia</Keyword><Keyword MajorTopicYN="N">Surveillance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30047946</ArticleId><ArticleId IdType="doi">10.24875/GMM.17003116</ArticleId><ArticleId IdType="pii">j154/3/283</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27507125</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1578-1852</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Season>Aug-Sep</Season></PubDate></JournalIssue><Title>Enfermedades infecciosas y microbiologia clinica</Title><ISOAbbreviation>Enferm Infecc Microbiol Clin</ISOAbbreviation></Journal><ArticleTitle>[Early diagnosis of anal intraepithelial neoplasia associated with human papillomavirus. What is the best strategy?].</ArticleTitle><Pagination><StartPage>397</StartPage><EndPage>399</EndPage><MedlinePgn>397-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eimc.2016.07.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0213-005X(16)30211-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burgos</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a; Vall d'Hebron Institut de Recerca, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curran</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a; Vall d'Hebron Institut de Recerca, Barcelona, Espa&#xf1;a. Electronic address: acurran@vhebron.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><VernacularTitle>Diagn&#xf3;stico precoz de las neoplasias intraepiteliales anales asociadas con el virus del papiloma humano &#xbf;Cu&#xe1;l es la mejor estrategia?</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Enferm Infecc Microbiol Clin</MedlineTA><NlmUniqueID>9104081</NlmUniqueID><ISSNLinking>0213-005X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002278" MajorTopicYN="N">Carcinoma in Situ</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="Y">Papillomaviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27507125</ArticleId><ArticleId IdType="doi">10.1016/j.eimc.2016.07.005</ArticleId><ArticleId IdType="pii">S0213-005X(16)30211-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16013791</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-4806</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>Actas urologicas espanolas</Title><ISOAbbreviation>Actas Urol Esp</ISOAbbreviation></Journal><ArticleTitle>[Which is the most appropriate diagnostic algorithm for prostate cancer screening?].</ArticleTitle><Pagination><StartPage>465</StartPage><EndPage>472</EndPage><MedlinePgn>465-72</MedlinePgn></Pagination><Abstract><AbstractText>Since the use of PSA to detect prostate cancer was generalised in the late 1980's, prostate cancer diagnosis has increased considerably. Although there is now indirect evidence pointing to the beneficial effect of screening, there are no data justifying PSA screening in the general population. There is also a controversy concerning the most appropriate algorithm, should screening be performed. Therefore, our aim was to review the literature and, based on our experience, attempt to define the best algorithm for prostate cancer screening. We have made a search on Medline using the following terms: prostate biopsy, screening, algorithms, radical prostatectomy, PSA and prostate cancer. After analysing the literature, we can confirm that there is no "definitive" algorithm, due to the rapid appearance and use of new technical and biological breakthroughs, although it appears that at this time, without ceasing to include a rectal examination, more value should be given to personal risk factors, including PSA, at ages under 50, with individual monitoring based on these factors. The algorithms applied to a population have first to be validated for the population concerned.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allepuz Losa</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Urologia, Hospital Universitario Miguel Server, Zaragoza. callepuz@salud.aragon.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borque Fernando</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rioja Sanz</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Cu&#xe1;l es el algoritmo diagn&#xf3;stico m&#xe1;s apropiado para el cribado del c&#xe1;ncer de pr&#xf3;stata?</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Urol Esp</MedlineTA><NlmUniqueID>7704993</NlmUniqueID><ISSNLinking>0210-4806</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16013791</ArticleId><ArticleId IdType="doi">10.1016/s0210-4806(05)73276-9</ArticleId><ArticleId IdType="pii">S0210-4806(05)73276-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>